TickerFacts.

Replimune Group, Inc. (REPL): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$316.59M
Year ended 2026-03-31
-$294.35M
Trailing 12 months to 2026-06-30
2017-03-31: -$9.53M2018-03-31: -$19.12M2019-03-31: -$30.80M2020-03-31: -$55.66M2021-03-31: -$78.24M2022-03-31: -$116.17M2023-03-31: -$174.63M2024-03-31: -$232.12M2025-03-31: -$258.12M2026-03-31: -$316.59M-$316.59M
2017-03-31 EBITDA (USD) 2026-03-31
Period endedEBITDAChange YoYSource filing
2026-03-31-$316.59Mn/m2026-06-29, From 2025-04-01
2025-03-31-$258.12Mn/m2026-06-29, From 2024-04-01
2024-03-31-$232.12Mn/m2025-05-22, From 2023-04-01
2023-03-31-$174.63Mn/m2024-05-16, From 2022-04-01
2022-03-31-$116.17Mn/m2023-05-18, From 2021-04-01
2021-03-31-$78.24Mn/m2022-05-19, From 2020-04-01
2020-03-31-$55.66Mn/m2021-05-20, From 2019-04-01
2019-03-31-$30.80Mn/m2020-06-03, From 2018-04-01
2018-03-31-$19.12Mn/m2020-06-03, From 2017-04-01
2017-03-31-$9.53Mn/a2019-06-28, From 2016-04-01

EBITDA at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Replimune Group, Inc. (REPL)2026-03-31-$316.59Mn/m
Prokidney Corp. (PROK)2025-12-31-$158.43Mn/m
Prime Medicine, Inc. (PRME)2025-12-31-$201.03Mn/m
Fate Therapeutics Inc (FATE)2025-12-31-$134.80Mn/m
C4 Therapeutics, Inc. (CCCC)2025-12-31-$113.26Mn/m
LENZ Therapeutics, Inc. (LENZ)2025-12-31-$90.85Mn/m
Scilex Holding Co (SCLX)2025-12-31-$341.38Mn/m
Kyverna Therapeutics, Inc. (KYTX)2025-12-31-$168.03Mn/m
Alector, Inc. (ALEC)2025-12-31-$150.29Mn/m

Compare REPL, PROK, PRME, FATE side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗